{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:58:22Z","timestamp":1793321902284,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006691","name":"Harvard Medical School","doi-asserted-by":"publisher","award":["George"],"award-info":[{"award-number":["George"]}],"id":[{"id":"10.13039\/100006691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006691","name":"Harvard Medical School","doi-asserted-by":"publisher","award":["Marie Vergottis Postdoctoral Fellowship"],"award-info":[{"award-number":["Marie Vergottis Postdoctoral Fellowship"]}],"id":[{"id":"10.13039\/100006691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Huiying Foundation","award":["Patricia K. Donahoe Award"],"award-info":[{"award-number":["Patricia K. Donahoe Award"]}]},{"DOI":"10.13039\/100007299","name":"Harvard Catalyst","doi-asserted-by":"publisher","award":["National Institutes of Health Award KL2 TR002542"],"award-info":[{"award-number":["National Institutes of Health Award KL2 TR002542"]}],"id":[{"id":"10.13039\/100007299","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the current era of effective adjuvant therapies and de-escalation of surgery, distinguishing which patients with high-risk stage II melanoma are at increased risk of recurrence after excision of the primary lesion is essential to determining appropriate treatment and surveillance plans.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A single-center retrospective study analyzed patients with stage IIB or IIC melanoma. Demographic and tumor data were collected, and genomic analysis of formalin-fixed, paraffin-embedded tissue samples was performed via an internal next-generation sequencing (NGS) platform (SNaPshot). The end points examined were relapse-free survival (RFS), distant metastasis-free survival (DMFS), overall survival (OS), and melanoma-specific survival (MSS). Uni- and multivariable Cox regressions were performed to calculate the hazard ratios.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 92 patients with a median age of 69 years and a male\/female ratio of 2:1. A Breslow depth greater than 4 mm, a higher mitotic rate, an advanced T stage, and a KIT mutation had a negative impact on RFS. A primary lesion in the head and neck, a mitotic rate exceeding 10 mitoses per mm<jats:sup>2<\/jats:sup>, a CDH1 mutation, or a KIT mutation was significantly associated with a shorter DMFS. Overall survival was significantly lower with older age at diagnosis and a higher mitotic rate. An older age at diagnosis also had a negative impact on MSS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Traditional histopathologic factors and specific tumor mutations displayed a significant correlation with disease recurrence and survival for patients with high-risk stage II melanoma. This study supported the use of genomic testing of high-risk stage II melanomas for prognostic prediction and risk stratification.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-023-14724-5","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T18:03:27Z","timestamp":1703873007000},"page":"2713-2726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma"],"prefix":"10.1245","volume":"31","author":[{"given":"Aikaterini","family":"Dedeilia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thinzar","family":"Lwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Tunsiricharoengul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleigha","family":"Lawless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Sharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve M.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"key":"14724_CR1","unstructured":"Survival Rates for Melanoma Skin Cancer. American Cancer Society, Atlanta, GA, published 2023, updated 1 March 2023. Retrieved 3 May 2023 at https:\/\/www.cancer.org\/cancer\/melanoma-skin-cancer\/detection-diagnosis-staging\/survival-rates-for-melanoma-skin-cancer-by-stage.html."},{"key":"14724_CR2","doi-asserted-by":"crossref","unstructured":"Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18:775\u201384.","DOI":"10.1080\/14737140.2018.1489246"},{"key":"14724_CR3","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al, Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472\u201392.","DOI":"10.3322\/caac.21409"},{"key":"14724_CR4","doi-asserted-by":"crossref","unstructured":"Swetter SM, Thompson JA, Albertini MR, et al. NCCN Guidelines\u00ae Insights: Melanoma: Cutaneous, version 2.2021: Featured updates to the NCCN guidelines. J Natl Comp Cancer Ntwk. 2021;19:364\u201376.","DOI":"10.6004\/jnccn.2021.0018"},{"key":"14724_CR5","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399:1718\u201329.","journal-title":"Lancet."},{"key":"14724_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41698-022-00269-5","volume":"6","author":"J Kaubryte","year":"2022","unstructured":"Kaubryte J, Lai AG. Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review. NPJ Precision Oncol. 2022;6:27.","journal-title":"NPJ Precision Oncol."},{"key":"14724_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","volume":"2016","author":"CD DiNardo","year":"2016","unstructured":"DiNardo CD, Cortes JE. Mutations in AML: prognostic and therapeutic implications. Hematol Am Soc Hematol Educ Program. 2016;2016:348\u201355.","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"14724_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11060-012-0938-9","volume":"110","author":"AS Chi","year":"2012","unstructured":"Chi AS, Batchelor TT, Dias-Santagata D, et al. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012;110:89\u201398.","journal-title":"J Neurooncol."},{"issue":"9","key":"14724_CR9","first-page":"100390","volume":"3","author":"AJ Cooper","year":"2022","unstructured":"Cooper AJ, Muzikansky A, Lennerz J, et al. Clinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant NSCLC. JTO Clin Res Rep. 2022;3(9):100390.","journal-title":"JTO Clin Res Rep."},{"key":"14724_CR10","doi-asserted-by":"crossref","unstructured":"Donnell E, Mahindra A, Yee AJ, et al. Clinical grade sNaPshot genetic mutation profiling in multiple myeloma. eBioMedicine. 2015;2:71\u20133.","DOI":"10.1016\/j.ebiom.2014.11.008"},{"key":"14724_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028585","volume":"6","author":"RJ Ryan","year":"2011","unstructured":"Ryan RJ, Nitta M, Borger D, et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLOS One. 2011;6:e28585.","journal-title":"PLOS One."},{"key":"14724_CR12","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/pcmr.12999","volume":"34","author":"SX Bian","year":"2021","unstructured":"Bian SX, Hwang L, Hwang J, et al. Acral lentiginous melanoma: population, treatment, and survival using the NCDB from 2004 to 2015. Pigment Cell Melanoma Res. 2021;34:1049\u201361.","journal-title":"Pigment Cell Melanoma Res."},{"key":"14724_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jdin.2020.07.004","volume":"1","author":"BM Tod","year":"2020","unstructured":"Tod BM, Schneider JW, Bowcock AM, Visser WI, Kotze MJ. The tumor genetics of acral melanoma: what should a dermatologist know? JAAD Int. 2020;1:135\u201347.","journal-title":"JAAD Int."},{"key":"14724_CR14","first-page":"116","volume":"11","author":"HM Hahn","year":"2019","unstructured":"Hahn HM, Lee KG, Choi W, Cheong SH, Myung KB, Hahn HJ. An updated review of mucosal melanoma: survival meta-analysis. Mol Clin Oncol. 2019;11:116\u201326.","journal-title":"Mol Clin Oncol."},{"key":"14724_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.semcancer.2019.09.013","volume":"61","author":"KW Nassar","year":"2020","unstructured":"Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. Semin Cancer Biol. 2020;61:139\u201348.","journal-title":"Semin Cancer Biol."},{"key":"14724_CR16","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","volume":"23","author":"GV Long","year":"2022","unstructured":"Long GV, Luke JJ, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022;23:1378\u201388.","journal-title":"Lancet Oncol."},{"key":"14724_CR17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/jamadermatol.2019.0440","volume":"155","author":"LA von Schuckmann","year":"2019","unstructured":"von Schuckmann LA, Hughes MCB, Ghiasvand R, et al. Risk of melanoma recurrence after diagnosis of a high-risk primary tumor. JAMA Dermatol. 2019;155:688\u201393.","journal-title":"JAMA Dermatol."},{"key":"14724_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/cam4.1320","volume":"7","author":"K Namikawa","year":"2018","unstructured":"Namikawa K, Aung PP, Gershenwald JE, Milton DR, Prieto VG. Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center. Cancer Med. 2018;7:583\u201393.","journal-title":"Cancer Med."},{"key":"14724_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2340\/00015555-2944","volume":"98","author":"S Ribero","year":"2018","unstructured":"Ribero S, Stucci LS, Marra E, et al. Effect of age on melanoma risk, prognosis, and treatment response. Acta Derm Venereol. 2018;98:624\u20139.","journal-title":"Acta Derm Venereol."},{"key":"14724_CR20","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3349\/ymj.2020.61.7.562","volume":"61","author":"DDM Pham","year":"2020","unstructured":"Pham DDM, Guhan S, Tsao H. KIT and melanoma: biological insights and clinical implications. Yonsei Med J. 2020;61:562\u201371.","journal-title":"Yonsei Med J."},{"key":"14724_CR21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ejca.2021.08.015","volume":"157","author":"T Steeb","year":"2021","unstructured":"Steeb T, Wessely A, Petzold A, et al. c-Kit inhibitors for unresectable or metastatic mucosal, acral, or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis. Eur J Cancer. 2021;157:348\u201357.","journal-title":"Eur J Cancer."},{"key":"14724_CR22","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1001\/jama.2011.746","volume":"305","author":"RD Carvajal","year":"2011","unstructured":"Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327\u201334.","journal-title":"JAMA."},{"key":"14724_CR23","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1073\/pnas.1918167117","volume":"117","author":"T-Y Na","year":"2020","unstructured":"Na T-Y, Schecterson L, Mendonsa AM, Gumbiner BM. The functional activity of E-cadherin controls tumor cell metastasis at multiple steps. Proc Natl Acad Sci. 2020;117:5931\u20137.","journal-title":"Proc Natl Acad Sci."},{"key":"14724_CR24","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/S0002-9440(10)65023-7","volume":"156","author":"MY Hsu","year":"2000","unstructured":"Hsu MY, Meier FE, Nesbit M, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol. 2000;156:1515\u201325.","journal-title":"Am J Pathol."},{"key":"14724_CR25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jid.2019.11.025","volume":"140","author":"SS Joshi","year":"2020","unstructured":"Joshi SS, Hornyak TJ. Cellular phenotypic plasticity of cutaneous melanoma: a complex puzzle. J Invest Dermatol. 2020;140:743\u20135.","journal-title":"J Invest Dermatol."},{"key":"14724_CR26","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani R, Akdemir Kadir C, Aksoy BA, et al. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681\u201396.","journal-title":"Cell."},{"key":"14724_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40257-018-0414-1","volume":"20","author":"D Meng","year":"2019","unstructured":"Meng D, Carvajal RD. KIT as an oncogenic driver in melanoma: an update on clinical development. Am J Clin Dermatol. 2019;20:315\u201323.","journal-title":"Am J Clin Dermatol."},{"key":"14724_CR28","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Genomic classification of cutaneous melanoma","year":"2015","unstructured":"Genomic classification of cutaneous melanoma. Cell. 2015;161:1681\u201396.","journal-title":"Cell."},{"key":"14724_CR29","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1038\/ncomms4401","volume":"5","author":"B Heidenreich","year":"2014","unstructured":"Heidenreich B, Nagore E, Rachakonda PS, et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun. 2014;5:3401.","journal-title":"Nat Commun."},{"key":"14724_CR30","doi-asserted-by":"publisher","first-page":"6300329","DOI":"10.1155\/2022\/6300329","volume":"2022","author":"Y Guo","year":"2022","unstructured":"Guo Y, Chen Y, Zhang L, et al. TERT Promoter mutations and telomerase in melanoma. J Oncol. 2022;2022:6300329.","journal-title":"J Oncol."},{"key":"14724_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov."},{"key":"14724_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:11.","journal-title":"Sci Signal."},{"issue":"12","key":"14724_CR33","doi-asserted-by":"publisher","first-page":"BSR20202794","DOI":"10.1042\/BSR20202794","volume":"40","author":"TH Chen","year":"2020","unstructured":"Chen TH, Chiu JY, Shih KH. A 23-gene prognostic classifier for prediction of recurrence and survival for Asian breast cancer patients. Biosci Rep. 2020;40(12):BSR20202794.","journal-title":"Biosci Rep."},{"key":"14724_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41408-020-0275-8","volume":"10","author":"A Ravindran","year":"2020","unstructured":"Ravindran A, He R, Ketterling RP, et al. The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. Blood Cancer J. 2020;10:7.","journal-title":"Blood Cancer J."},{"key":"14724_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12890-021-01803-0","volume":"22","author":"P Paliogiannis","year":"2022","unstructured":"Paliogiannis P, Colombino M, Sini MC, et al. Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study. BMC Pulmonary Med. 2022;22:32.","journal-title":"BMC Pulmonary Med."},{"key":"14724_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/TACG.S69210","volume":"9","author":"H Helgadottir","year":"2016","unstructured":"Helgadottir H, H\u00f6iom V. The genetics of uveal melanoma: current insights. Appl Clin Genet. 2016;9:147\u201355.","journal-title":"Appl Clin Genet."},{"key":"14724_CR37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.21037\/atm.2020.02.132","volume":"8","author":"LB Song","year":"2020","unstructured":"Song LB, Zhang QJ, Hou XY, et al. A twelve-gene signature for survival prediction in malignant melanoma patients. Ann Transl Med. 2020;8:312.","journal-title":"Ann Transl Med."},{"key":"14724_CR38","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jaad.2022.06.1202","volume":"87","author":"A Jarell","year":"2022","unstructured":"Jarell A, Gastman BR, Dillon LD, et al. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test. J Am Acad Dermatol. 2022;87:1312\u201320.","journal-title":"J Am Acad Dermatol."},{"key":"14724_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","volume":"21","author":"P Gerami","year":"2015","unstructured":"Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21:175\u201383.","journal-title":"Clin Cancer Res."},{"key":"14724_CR40","doi-asserted-by":"crossref","unstructured":"Whitman ED, Koshenkov VP, Gastman BR, et al. Integrating 31-gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction. JCO Precision Oncol. 2021:1466\u201379.","DOI":"10.1200\/PO.21.00162"},{"key":"14724_CR41","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2159-8290.CD-22-0427","volume":"13","author":"S Suresh","year":"2023","unstructured":"Suresh S, Rabbie R, Garg M, et al. Identifying the transcriptional drivers of metastasis embedded within localized melanoma. Cancer Discov. 2023;13:194\u2013215.","journal-title":"Cancer Discov."},{"key":"14724_CR42","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41467-021-21207-2","volume":"12","author":"M Garg","year":"2021","unstructured":"Garg M, Couturier D-L, Nsengimana J, et al. Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nat Commun. 2021;12:1137.","journal-title":"Nat Commun."},{"issue":"4","key":"14724_CR43","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.3390\/ijerph19042331","volume":"19","author":"M Dieng","year":"2022","unstructured":"Dieng M, Turner RM, Lord SJ, et al. Cost-effectiveness of PET\/CT surveillance schedules to detect distant recurrence of resected stage III melanoma. Int J Environ Res Public Health. 2022;19(4):2331.","journal-title":"Int J Environ Res Public Health."},{"key":"14724_CR44","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/pcmr.12907","volume":"34","author":"AT Young","year":"2021","unstructured":"Young AT, Vora NB, Cortez J, et al. The role of technology in melanoma screening and diagnosis. Pigment Cell Melanoma Res. 2021;34:288\u2013300.","journal-title":"Pigment Cell Melanoma Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14724-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14724-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14724-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:05:37Z","timestamp":1709424337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14724-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["14724"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14724-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]},"assertion":[{"value":"14 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Genevieve Boland discloses the following financial and professional collaborations:Takeda Oncology: sponsored research agreement,\nOlink Proteomics: sponsored research agreement,\nNovartis: scientific advisory board, speaker,\nNektar Therapeutics: scientific advisory board, steering committee,\nPalleon Pharmaceuticals: sponsored research agreement,\nInterVenn Biosciences: sponsored research agreement, scientific advisory board,\nMerck: scientific advisory board, consulting,\nIovance: scientific advisory board,\nAnkyra Therapeutics: scientific advisory board, equity.All other authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}